Filing Flows › NovoCure (NVCR) › Q3 2026 › vs Q2 2026
NovoCure (NVCR) Q3 2026 vs Q2 2026 (quarter over quarter)
NovoCure's revenue rose $9.8M (+5%) from $184M in Q2 2026 to $193M in Q3 2026.
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 8.1% | 0.7% | +7.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $193M | $184M | $9.8M | +5% |
| Net loss | $10.4M | $15.7M | −$5.2M | -33% |
| Costs & expenses | $204M | $199M | $4.6M | +2% |
| Operating costs | $200M | $194M | $5.4M | +3% |
| Interest & other, net | $1.7M | $1.9M | −$181K | -10% |
| Income tax | $2.6M | $3.2M | −$651K | -20% |
| Cost of revenue | $44.5M | $41.1M | $3.4M | +8% |
| Research & development | $58.1M | $51.4M | $6.7M | +13% |
| Sales & marketing | $53.3M | $61.7M | −$8.4M | -14% |
| General & admin | $43.6M | $39.9M | $3.7M | +9% |
| Operating cash sources | $33.1M | $23.8M | $9.3M | +39% |
| Depreciation & amortization | $4.4M | $4.3M | $109K | +3% |
| Share-based compensation | $17.5M | $17.0M | $471K | +3% |
| Working capital & other | $11.2M | $2.5M | $8.7M | +353% |
| Net loss absorbed | $10.4M | $15.7M | −$5.2M | -33% |
| Operating cash flow | $22.7M | $8.1M | $14.5M | +179% |
| Free cash flow (OCF − capex) | $15.7M | $1.2M | $14.5M | 13× |
| Capital expenditures | $6.9M | $6.9M | $5K | +0.1% |
Questions
How much did NovoCure's revenue grow quarter over quarter in Q3 2026?
NovoCure's revenue rose $9.8M (+5%) from $184M in Q2 2026 to $193M in Q3 2026.